#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neurotrophic keratopathy Necrotising myositis Necrotising enterocolitis neonatal Paroxysmal nocturnal haemoglobinuria B precursor type acute leukaemia Hereditary spastic paraplegia Ovarian epithelial cancer Arteriovenous malformation MELAS syndrome Myotonia Cystic fibrosis Nephroblastoma Polycystic liver disease Thyroid cancer metastatic Central nervous system neoplasm More trials…

    Learn about Rare Diseases

    Leukoencephalopathy X-linked lymphoproliferative syndrome Tuberous sclerosis complex Crigler-Najjar syndrome – Life with Disease Hereditary optic atrophy – Diagnostics Ewing’s sarcoma metastatic – Trials in Disease Noonan syndrome – Basic Information Niemann-Pick disease – Trials in Disease Propionic acidaemia – Treatment Skin angiosarcoma – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Metolazone Iptacopan Hydrochloride E.coli Polysaccharide Calcium Pitavastatin Calcium Tucatinib L-Tyrosine Ace Inhibitors, Plain Azd9550 Pegvaliase Nizaracianine Triflutate XMAB942 Crizanlizumab Dexamethasone Acetate Trastuzumab Emtansine Potassium Canrenoate Ramucirumab Mifepristone Nicotinamide Bp GXV813 More therapies…

    Learn about Your Condition

    Adenocarcinoma of colon Follicular lymphoma stage IV Seizure Bronchiectasis Huntington's disease Thermal burn Autism spectrum disorder Dry eye Rheumatic disorder Bile duct cancer Lyme disease Carcinoid syndrome Acute on chronic liver failure Prodromal Alzheimer's disease Bone marrow failure More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Regional Du Cancer De Montpellier

Institut Regional Du Cancer De Montpellier

208 Avenue Des Apothicaires, Montpellier, 34298, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Dostarlimab and Niraparib for Patients with Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Endometrial cancer recurrent
    • Endometrial cancer
    • Ovarian cancer
    Investigated Drugs:
    • Dostarlimab
    • Niraparib Tosilate Monohydrate
    France Italy Spain

  • Study on Durvalumab and Tremelimumab for Patients with Kidney Cancer at Risk of Recurrence After Surgery

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Renal cell carcinoma
    Investigated Drugs:
    • Tremelimumab
    • Durvalumab
    France Spain

  • Study on Reducing Treatment for Patients with HER2-Positive Metastatic Breast Cancer Using Trastuzumab and Drug Combination After 2 Years of Controlled Disease

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    Investigated Drugs:
    • Trastuzumab Emtansine
    • Pertuzumab
    • Trastuzumab
    France

  • Study of petosemtamab alone or with drug combination for patients with advanced colorectal cancer and other solid tumors

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    • Neoplasm malignant
    Investigated Drugs:
    • Calcium Folinate
    • Fluorouracil
    • Irinotecan
    Belgium France Italy The Netherlands Spain

  • Study on Adjusting Chemotherapy with Carboplatin and Paclitaxel for Patients with Poor Prognostic Ovarian Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Bevacizumab
    • Carboplatin
    • Filgrastim
    France Italy The Netherlands

  • Adjuvant Datopotamab Deruxtecan with Drug Combination in Patients with High‑Risk Muscle‑Invasive Urothelial Carcinoma

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma
    Investigated Drugs:
    • Enfortumab Vedotin
    • Datopotamab Deruxtecan
    • Durvalumab
    France Germany Italy Poland Spain

  • Phase 1/2 First‑in‑Human Study of Oral GSK5471713B in Adults with Metastatic Castration‑Resistant Prostate Cancer

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Prostate cancer
    France The Netherlands Spain

  • Study of denikitug alone or in drug combination in adults with advanced microsatellite stable colorectal cancer

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal cancer
    Investigated Drugs:
    • Tipiracil Hydrochloride
    • Trifluridine
    • Bevacizumab
    France Italy Spain

  • Phase I/II Study of ubamatamab plus drug combination in patients with ovarian cancer who have poor response to first‑line chemotherapy

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • Ubamatamab
    • Bevacizumab
    • Carboplatin
    France

  • 68Ga-FAPI-46 PET-CT for Initial Staging of Gastric Cancer in Patients Eligible for Curative Treatment

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Gastric cancer
    Investigated Drugs:
    • (S)-2,2′,2”-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
    • Gallium (68Ga) Chloride
    • Germanium (68Ge) Chloride
    France
Previous Page
1 … 8 9 10 11 12 … 25
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!